BioSpectrum the business of Bio & Health Sciences ASIA EDITION

Boston Scientific embolization tech gets FDA nod

20 November 2013 | Regulatory | By BioSpectrum Bureau

Singapore: Boston Scientific has received the US FDA's clearance and CE Mark approval for its Direxion Torqueable Microcatheter, bolstering its portfolio of peripheral embolization technologies.

Peripheral embolization is a technique used primarily by interventional radiologists to treat liver cancer, uterine fibroids and other challenging conditions. It involves deliberately blocking a blood vessel to prevent blood flow to an area of the body, which can effectively shrink a tumor or block an aneurysm.

"The Direxion Microcatheter's unique handling characteristics are intended to enable physicians to efficiently access difficult to navigate vessels across many types of peripheral embolization procedures," said Mr Riad Salem, professor of radiology and director of interventional oncology at Northwestern Memorial Hospital.

"Combined with a range of tip shape offerings and selection of pre-loaded systems, the Direxion Microcatheter offers an attractive portfolio that opens up a whole new dimension in microcatheter technology," said Mr Robert Lewandowski, associate professor of radiology at Northwestern Memorial Hospital.